Is Vericel Corp (VCEL) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 5.6% / 30% | 8.0% / 30% | 4.9% / 30% | 2.54% / 5% | ✓ HALAL |
| DJIM | 5.6% / 33% | 8.0% / 33% | 4.9% / 33% | 2.54% / 5% | ✓ HALAL |
| MSCI | 19.7% / 33% | 28.2% / 33% | 17.3% / 33% | 2.54% / 5% | ✓ HALAL |
| S&P | 5.6% / 33% | 8.0% / 33% | 4.9% / 33% | 2.54% / 5% | ✓ HALAL |
| FTSE | 19.7% / 33% | 28.2% / 33% | 17.3% / 50% | 2.54% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 74.4% | |
| Operating Margin | 24.1% | |
| Net Margin | 6.0% | |
| Return on Equity (ROE) | 5.1% | |
| Return on Assets (ROA) | 1.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $52M |
| Free Cash Flow | $25M |
| Total Debt | $96M |
| Debt-to-Equity | 27.3 |
| Current Ratio | 5.0 |
| Total Assets | $488M |
Price & Trading
| Last Close | $30.82 |
| 50-Day MA | $35.23 |
| 200-Day MA | $36.51 |
| Avg Volume | 523K |
| Beta | 1.2 |
|
52-Week Range
$28.95
| |
About Vericel Corp (VCEL)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Purification Calculator
As a halal stock with 2.54% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Vericel Corp (VCEL) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Vericel Corp is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Vericel Corp's debt ratio?
Vericel Corp's debt ratio is 5.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 19.7%.
Does Vericel Corp require dividend purification?
Yes, Vericel Corp has an impermissible income ratio of 2.54%, which means 2.54% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Vericel Corp's key financial metrics?
Vericel Corp has a market capitalization of $1.5B, trailing P/E ratio of 91.7, and revenue of $276M. The company maintains a gross margin of 74.4% and a net margin of 6.0%. Return on equity stands at 5.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.